Skip to main content

Bridgebio Pharma

BridgeBio Pharma Inc is an American commercial-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers. The company discovers, develops, and commercializes targeted small molecules, gene therapies, and biologics, including acoramidis for transthyretin amyloidosis. Main revenue drivers include commercial drug sales, strategic biopharmaceutical partnership milestones, and licensing agreements. BridgeBio Pharma serves rare disease patients, clinical research centers, and specialized healthcare providers across North America and international markets. The company holds a prominent position in precision biopharmaceutical development for rare genetic disorders. Headquartered in Palo Alto, California, BridgeBio Pharma Inc is listed on the Nasdaq Stock Market.

14 of the funds FundTelligence covers report a position in Bridgebio Pharma.

Sector
Health Care
Country
United States
Funds holding it
14

Funds holding Bridgebio Pharma

Showing the 8 largest of 14 funds holding it.

Loading...